Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596697 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Volunteers
A Phase 1 study, sponsored by Hepion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT03596697: Completed Phase 1 study, sponsored by Hepion Pharmaceuticals.
NCT03596697 is a Phase 1 study that has completed, run by Hepion Pharmaceuticals. The registered enrollment target is 92 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03596697, a Phase 1 study, has completed, sponsored by Hepion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is three part study that will, in part one assess the safety, tolerability, and PK of a single dose of CRV431 in healthy volunteers. The second part of the study will be a single dose drug-drug interaction study in healthy volunteers with CRV431 co-treated with TDF. The third part of the study will assess the safety, tolerability, PK, and preliminary signal for antiviral efficacy and identification of clinically-relevant biomarkers of CRV431 with TDF in stable HBV patients.
Interventions
- DRUG Placebo
- DRUG TDF
- DRUG CRV431
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2019-07-09 |
| Est. Completion | 2021-06-04 |
| Phase | Phase 1 |
What the finished NCT03596697 record still lists
NCT03596697 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03596697 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03596697 about?
NCT03596697 is a clinical study titled "A Study in Healthy Volunteers". This is three part study that will, in part one assess the safety, tolerability, and PK of a single dose of CRV431 in healthy volunteers. The second part of the study will be a single dose drug-drug interaction study in healthy volunteers with CRV431 co-treated with TDF. The third part of the study ...
What is the current status of trial NCT03596697?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2019-07-09. Estimated completion is 2021-06-04.
What interventions are being tested in trial NCT03596697?
The interventions under investigation include: Placebo (DRUG), TDF (DRUG), CRV431 (DRUG).
Who is sponsoring clinical trial NCT03596697?
This trial is sponsored by Hepion Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03596697's enrollment target sits among peer trials
92 625th of 2000 higher than 1,375 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI